Use of 17-oxyprogesterone-capronate in genital endometriosis
article
OA: closed
CC0
AI-generated summary
This paper examines the use of 17-oxyprogesterone-capronate as a hormone therapy for genital endometriosis, noting that endometroid heterotopias develop due to hormonal imbalances involving increased estrogen and insufficient corpus luteum function.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Among the existing treatments for endometriosis patients, hormone therapy has attracted particular attention in recent years. Experimental and clinical observations have established that the growth and development of endometroid heterotopias occurs against a background of hormonal imbalance in the female body. An increased secretion of oestrogenic hormones and an insufficient function of corpus luteum hormone play a major role.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK